Valuation : Agenus Inc.

Market Cap 309M 266M 250M 228M 427M 29.39B 428M 2.97B 1.15B 14.97B 1.16B 1.13B 47.43B P/E 2026 *
10.1x
P/E 2027 * -28x
Enterprise Value 309M 266M 250M 228M 427M 29.39B 428M 2.97B 1.15B 14.97B 1.16B 1.13B 47.43B EV / Sales 2026 *
2.2x
EV / Sales 2027 * 2.25x
Free-Float
93.77%
Yield 2026 *
-
Yield 2027 * -
01:21pm Agenus Inc. Presents Three-Year Overall Survival Data for Botensilimab Plus Balstilimab in Recurrent Ovarian Cancer CI
08-28 Agenus Reports Peer-Reviewed Publication of Mature Phase 1B Results for Botensilimab Plus Balstilimab in Microsatellite-Stable Metastatic Colorectal Cancer CI
08-26 Agenus Reports Updated Nest Phase 2 Results for Neoadjuvant Botensilimab and Balstilimab in Resectable Colon Cancer CI
08-11 Agenus Inc. Announces Appointment of Marco Tullio Marcucci as Director and as A Member of Corporate Governance and Nominating Committee, Effective August 5, 2026 CI
08-07 Agenus Files for Resale of Up to 78 Million Shares MT
08-07 Agenus Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-30 B. Riley Adjusts Agenus Price Target to $14 From $8, Maintains Buy Rating MT
07-14 Agenus Inc. announced that it has received $85 million in funding from RA Capital Management, L.P., Ligand Pharmaceuticals Incorporated, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, Investment Arm CI
07-13 MGM Rises on Takeover Bid; SK Hynix Falls on Memory Pullback | Stock Movers MT
07-13 Agenus Inc. - Special Call
07-13 Agenus Signs Deal to Sell Up to $340 Million Worth of Securities; Shares Up Pre-Bell MT
07-06 Agenus Reports Three-Year Landmark Phase 1b Data For Botensilimab Plus Balstilimab In Refractory Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases CI
07-06 Agenus' Potential Colorectal Cancer Combination Shows 21.2-Month Survival MT

Last Transcript : Agenus Inc.

1 day-7.67%
1 week-15.20%
Current month-9.86%
1 month-1.44%
3 months+120.58%
6 months+117.78%
Current year+118.47%
1 week 6.78
Extreme 6.782
8.38
1 month 6.42
Extreme 6.42
8.73
Current year 2.71
Extreme 2.71
8.85
1 year 2.71
Extreme 2.71
8.85
3 years 1.38
Extreme 1.38
27.2
5 years 1.38
Extreme 1.38
131.2
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 73 30/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 31/10/2021
Director TitleAgeSince
Chairman 73 03/11/2010
Director/Board Member 68 07/03/2007
Director/Board Member 68 06/12/2006
Date Insider Type Main position Quantity % Market Cap. Importance
10/08/26 Free

Chief Executive Officer

1,971,500 4.4054%
05/08/26 Free

Director

50,000 0.1117%
05/08/26 Free

Director

50,000 0.1117%
Change 5-day change 1-year change 3-year change Capi.($)
-7.67%-15.20%+35.31%-72.11% 309M
+0.67%-6.91%-2.66%+11.21% 46.38B
+0.17%-0.74%+407.28%+546.58% 44.51B
-0.86%-2.60%+35.51%+20.35% 42.3B
-0.14%-2.98%-0.04%+82.21% 39.91B
0.00%-1.72%+13.42%+42.33% 32.79B
-3.44%-2.43% - - 17.13B
-0.78%-1.13%+20.74%+116.26% 16.36B
+0.59%-2.86%+13.38%+31.71% 14.31B
-0.86%-4.60%+76.86%+39.36% 13.29B
Average -1.37%-4.12%+66.65%+90.88% 26.73B
Weighted average by Cap. -0.53%-3.05%+85.98%+132.86%

Financials

2026 *2027 *
Net sales 140M 121M 114M 104M 194M 13.35B 195M 1.35B 521M 6.8B 527M 515M 21.55B 137M 118M 111M 101M 190M 13.07B 190M 1.32B 510M 6.66B 516M 505M 21.09B
Net income 35.2M 30.29M 28.52M 25.99M 48.62M 3.35B 48.82M 338M 131M 1.71B 132M 129M 5.41B -26.1M -22.46M -21.15M -19.27M -36.05M -2.48B -36.2M -251M -96.87M -1.27B -98.01M -95.88M -4.01B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. The Company's primary business is immuno-oncology, which is advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients from immunotherapy. Its lead clinical program is botensilimab, alone and in combination with balstilimab, is a clinical-stage immuno-oncology asset which may be used as standalone agents or be complimentary to botensilimab plus balstilimab. Its internal discovery and translation platforms support target identification, antibody generation, biomarker analysis, and candidate selection. The Company's clinical and preclinical portfolio include agents directed to CTLA-4, PD-1, CD137, CD73/TGF-beta, ILT2, LAG-3, TIM-3, and TIGIT, all of which remain as proprietary assets of Agenus.
Employees
81
Date Price Change Volume
09/09/26 US$6.860 -7.67% 1,445,780
08/09/26 US$7.430 -9.83% 1,207,777
04/09/26 US$8.240 0.00% 986,848
03/09/26 US$8.240 +1.85% 738,723
02/09/26 US$8.090 +1.25% 663,995
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.860USD
Average target price
19.50USD
Spread / Average Target
+184.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!